Report cover image

Advanced Kidney Cancer Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20146851

Description

Kidney cancer, characterized by the uncontrolled growth of malignant cells in the kidneys, is a significant global health challenge, with an estimated 400,000 new cases annually and nearly 175,000 deaths per year. The disease is commonly treated with first-line therapies, including immune checkpoint inhibitors and targeted therapies. However, a high unmet clinical need for more effective treatments remains, as current options often result in limited patient outcomes. The growing focus on immunotherapies, targeted treatments, and combination therapies is expected to drive the development of promising pipeline drugs, offering hope for improved survival rates and quality of life for patients in the future.

Report Coverage

The Advanced Kidney Cancer Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into advanced kidney cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for advanced kidney cancer. The advanced kidney cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The advanced kidney cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with advanced kidney cancer treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to advanced kidney cancer.

Advanced Kidney Cancer Drug Pipeline Outlook

Advanced kidney cancer occurs when cancer cells grow uncontrollably in the kidneys, often spreading to other organs. It typically presents as clear-cell renal cell carcinoma (ccRCC), the most common form. Factors like smoking, obesity, and hypertension increase the risk of developing advanced kidney cancer. Early-stage cancers are treatable, but advanced stages are harder to manage, creating a significant clinical need for new therapies.

Advanced kidney cancer is primarily treated with targeted therapies, including tyrosine kinase inhibitors, and immune checkpoint inhibitors like nivolumab and pembrolizumab. Combination treatments, such as immunotherapy combined with targeted agents, are also increasingly used. These therapies aim to slow tumor growth and improve patient survival, addressing the significant unmet need for more effective treatment options in advanced stages.

Advanced Kidney Cancer Epidemiology

The advanced kidney cancer drug pipeline is crucial in addressing the increasing incidence of renal cell carcinoma, which affects approximately 9 individuals per 100,000 people annually in Spain. In the United States, approximately 81,800 new cases and 14,890 deaths from renal cell carcinoma and other kidney tumors were estimated in 2023. About 50% of cases are localized, while 25% are diagnosed with advanced or regional kidney cancer.

Advanced Kidney Cancer – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of advanced kidney cancer drug candidates based on several segmentations, including:

By Phase
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class
  • Small Molecules
  • Monoclonal Antibodies
  • Gene Therapies
By Route of Administration
  • Oral
  • Parenteral
  • Others
Advanced Kidney Cancer – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase I covers a major share of the total advanced kidney cancer clinical trials.

Advanced Kidney Cancer Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the advanced kidney cancer pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for advanced kidney cancer.

Advanced Kidney Cancer Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the advanced kidney cancer report insights includes the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in advanced kidney cancer clinical trials:
  • Bristol-Myers Squibb
  • AstraZeneca
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • Huabo Biopharm Co., Ltd.
  • Chongqing Precision Biotech Co., Ltd.
  • Osel, Inc.
  • Pfizer
  • NiKang Therapeutics, Inc.
Advanced Kidney Cancer Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for advanced kidney cancer. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of advanced kidney cancer drug candidates.

Drug: TQB2450, Anlotinib, Sunitinib

The study, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., aims to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus sunitinib in patients with advanced renal cancer. This Phase 3 trial involves 528 participants and is expected to be completed by June 2025, with primary completion projected for December 2025.

Drug: Cabozantinib

The Phase II clinical trial sponsored by Emory University evaluates neoadjuvant cabozantinib for treating patients with locally advanced non-metastatic clear cell renal cell carcinoma before surgery. The primary objective is to assess the objective response rate following 12 weeks of treatment. The study is expected to be completed by February 2025 and has enrolled 22 participants.

Reasons To Buy This Report

The Advanced Kidney Cancer Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for advanced kidney cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within advanced kidney cancer pipeline insights.

Key Questions Answered in the Advanced Kidney Cancer – Pipeline Insight Report
  • What is the current landscape of advanced kidney cancer pipeline drugs?
  • Which companies/institutions are developing advanced kidney cancer emerging drugs?
  • How many phase II drugs are currently present in advanced kidney cancer pipeline drugs?
  • Which company is leading the advanced kidney cancer pipeline development activities?
  • What is the current advanced kidney cancer therapeutic assessment?
  • What are the opportunities and challenges present in the advanced kidney cancer drug pipeline landscape?
  • What is the efficacy and safety profile of advanced kidney cancer pipeline drugs?
  • Which companies/institutions are involved in advanced kidney cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in advanced kidney cancer?
Related Reports

Bladder Cancer Market Report

Global Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Advanced Kidney Cancer
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile: Advanced Kidney Cancer
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Advanced Kidney Cancer: Epidemiology Snapshot
5.1 Advanced Kidney Cancer Incidence by Key Markets
5.2 Advanced Kidney Cancer – Patients Seeking Treatment in Key Markets
6 Advanced Kidney Cancer: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Advanced Kidney Cancer: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Advanced Kidney Cancer, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Advanced Kidney Cancer Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Advanced Kidney Cancer Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: TQB2450, Anlotinib, Sunitinib
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Biological: Nivolumab, Ipilimumab
10.2.3 Other Drugs
11 Advanced Kidney Cancer Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: Cabozantinib
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Drug: HB0025
11.2.3 Other Drugs
12 Advanced Kidney Cancer Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Biological: CD70 CAR-T cells
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Advanced Kidney Cancer Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Advanced Kidney Cancer, Key Drug Pipeline Companies
14.1 Bristol-Myers Squibb
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 AstraZeneca
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Huabo Biopharm Co., Ltd.
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Chongqing Precision Biotech Co., Ltd.
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Osel, Inc.
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Pfizer
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
14.8 NiKang Therapeutics, Inc.
14.8.1 Company Snapshot
14.8.2 Pipeline Product Portfolio
14.8.3 Financial Analysis
14.8.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us